Adamis Pharmaceuticals Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.006945 million compared to USD 0.039847 million a year ago. Net loss was USD 8.57 million compared to USD 8.4 million a year ago. Basic loss per share from continuing operations was USD 2.79 compared to USD 3.89 a year ago. Basic loss per share was USD 3.4 compared to USD 3.92 a year ago.
For the six months, sales was USD 1.46 million compared to USD 1.19 million a year ago. Net loss was USD 17.52 million compared to USD 18.75 million a year ago. Basic loss per share from continuing operations was USD 6.81 compared to USD 8.66 a year ago. Basic loss per share was USD 7.44 compared to USD 8.77 a year ago.